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ABSTRACT 
Endogenous opioids participate in the regulation of gonadotropin 
secretion through an influence on the release of the hypothalamic 
LHRH. However, it is not clear whether opioids exert a direct effect 
on LHRH-producing neurons or interfere with other systems able to 
influence LHRH release. 
A neuronal LHRH-producing cell line (GTl) developed recently 
provides a good model to study the mechanisms controlling LHRH 
release. In the present study, the presence of opioid receptors on a 
subclone of GTl cells (GTl-1) has been investigated. A specific and 
saturable binding of the 3H-labeled nonselective opioid ligand di- 
prenorphine (r3HlDIP) was detected by a receptor binding assay on 
both intact GTl-1 cells and crude membrane preparations obtained 
from these cells. Analysis of saturation curves revealed that L3HlDIP 
apparently binds to a single class of sites with a & of 0.2 nM and a 
binding capacity of 125 fmol/mg protein, corresponding to approxi- 
mately 20,000 sites/cell. Selective displacement of the binding of 
L3HlDIP to GTl-1 cells by [D-Ala’JV-Me-Phe4,Gly6-ollenkephalin, 
[D-Pen’&)-Pen5]enkephalin (DPDPE), and U50488H, which are se- 
lective ligands, respectively, for p-, 6-, and K-receptors, was also eval- 
uated. Only the specific &ligand DPDPE produced a significant in- 
hibition of the binding of L3HlDIP. [D-Ala’n-Me-Phe4,Glv5- 
ol]Enkephalin and U50488H were totally ineffective. The inhibit&y 
effect of the aeonist DPDPE on the bindine of T3H1DIP was decreased 
by the presence of sodium ions, a typical &a&cte&tic of the binding 
of agonists to opioid receptors. Finally, it has been observed that 
treatment with prostaglandins E, and E, produces a dramatic in- 
crease in CAMP accumulation in GTl-1 cells, and DPDPE is hirzhlv 
effective in suppressing this effect. On the basis of these results,% & 
possible to postulate the presence of functional S-opioid receptors on 
GTl-1 cells. By extrapolation, one might suggest that endogenous 
opioids may affect LHRH neurons by two mechanisms: a direct one, 
acting via a-receptors, and an indirect one, through the activation of 
neurons impinging on the LHRH system, which uses p-receptors. 
(Endocrinology 136: 289-295, 1995) 
T HE SECRETION of anterior pituitary gonadotropins is under the control of the hypothalamic hormone LHRH 
(1, 2). Several studies have shown that the neurons that 
synthesize LHRH are innervated by multiple neuronal path- 
ways, which use different neurotransmitter systems. It is via 
these pathways that extrahypothalamic structures may mod- 
ify LHRH release and, consequently, modulate gonado- 
tropin secretion (3, 4). The study of the neurons that syn- 
thesize LHRH is made difficult by the peculiar anatomy of 
the LHRH system, which is composed of only a few hundred 
neurons scattered in the hypothalamic area. 
A promising tool for the investigation of these interactions 
became available recently, when an immortalized line of 
LHRH-producing neurons (the GTl cell line) was developed; 
this was obtained by targeted tumorigenesis in transgenic 
mice (5). The three subclones of the GTl cells so far obtained 
(GTI-1, GTl-3, and GTl-7) (5) show the phenotypic char- 
acteristics of neuronal cells and synthesize and secrete abun- 
dant amounts of LHRH (5-7). If one assumes that these cell 
lines reflect the biological characteristics of physiological 
LHRH-synthesizing neurons, they may be used to extend our 
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knowledge on the physiology of LHRH-secreting cells. Re- 
cently, it has been shown that the GTl cells possess the 
receptors for several families of neurotransmitters known to 
modify LHRH secretion, such as those for norepinephrine (8, 
9), dopamine (9, lo), y-aminobutyric acid (ll), excitatory 
amino acids (12, 13), endothelin (14), etc. 
It is known that among the transmitters involved in the 
control of LHRH release, the endogenous opioid peptides 
(Met- and Leu-enkephalin, dynorphin, and /3-endorphin) 
play a particularly relevant role (1, 15-18). It has been re- 
peatedly shown that opioid agonists (e.g. morphine) inhibit 
gonadotropin release, and that opioid antagonists (e.g. nal- 
oxone) stimulate LH output (19-21). However, little is 
known about the site where opioids act to modulate gona- 
dotropin secretion. There is no clear-cut evidence on a pos- 
sible direct effect of natural and synthetic opioids on LHRH- 
producing neurons, because of the methodological difficulty 
in studying LHRH neurons in viva. The majority of the re- 
ports available support the view that the effects of opioids on 
the LHRH-secreting system might be indirect, via the inter- 
action with intermediate neuronal systems that influence 
LHRH secretion through the release of their specific neuro- 
transmitters (18). 
As no data are available on the presence of opioid recep- 
tors on the neurons synthesizing LHRH, it was felt to be of 
interest to verify whether opioid receptors might be present 
on GTl cells. To this purpose, the possible binding of the 
nonselective opioid ligand diprenorphine (DIP) on GTl-1 
cells was first analyzed, using both membrane preparations 
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and intact cells. As it is known that opioids exert their effects 
through the interaction with at least three subclasses of spe- 
cific binding sites (named, respectively, /.L, 6, and K) (22,231, 
it was subsequently attempted to clarify whether one or more 
subclasses of opioid receptors might be present on this 
LHRH-producing cell line. 
Materials and Methods 
Cell cultures 
GTI-1 cells, generously provided by Dr. R. I. Weiner (San Fran- 
cisco, CA) through Dr. B. Marchetti (Catania, Italy), were routinely 
grown in monolayer at 37 C in a humidified CO, incubator in Dulbecco’s 
Minimum Essential Medium containing 1 mM sodium pyruvate, 100 
pg/ml streptomycin, 100 U/ml penicillin, and 10 mg/liter phenol red 
(Biochrom KG, Berlin, Germany) and supplemented with 10% fetal calf 
serum (Gibco, Grand Island, NY). The medium was replaced at 2-day 
intervals. Subconfluent cells were routinely harvested by trypsinization 
and seeded in 57-cm* dishes (1 X lo6 cells) for propagation. GTl-1 cells 
within six passages were used throughout the experiments. To obtain 
crude cell membrane preparations, GTl-1 cells at subconfluence were 
harvested in Dulbecco’s PBS solution (DPBS) without calcium and mag- 
nesium salts and containing 0.4% EDTA; the cellular pellet, obtained by 
centrifugation, was subsequently washed in DPBS. The cells were then 
homogenized in 0.32 M sucrose solution in 5 mM Tris-HCl, pH 7.4, by 
seven strokes in a glass-Teflon potter kept in ice. The cell homogenate 
was then centrifuged (750 X g at 4 C for 10 min); the resulting super- 
natants were incubated for 30 min at 37 C and then further centrifuged 
30 min at 40,000 X g at 4 C. The supematant was decanted, and the pellet 
(crude membrane preparation) was used in the receptor binding assay. 
For receptor binding assay on intact cells and CAMP experiments, 
GTl-1 cells were plated in 12-or 24-wells plates (0.5 X lo6 cells/cm? 
and used after 3 days of culture. All samples were assayed for protein 
content using a microassay (24) with human serum albumin as a 
standard. 
Receptor binding assay 
The receptor binding assay was performed using [15,15-N-3HIDIP 
(SA, 31 Ci/mmol; Amersham, Milan, Italy) as opioid ligand. The binding 
assay on crude membrane preparations was performed as previously 
described (25). The competition curves were performed by incubation of 
0.1 nM 13H1DIP in the absence and presence of the selective opioid 
agonists [o-Ala’,N-Me-Phe4,G1y5-ollenkephalin (DAGO), [o-Per?,o- 
Pen5]enkephalin (DPDPE; Sigma Chemical Co., St. Louis, MO), and 
trans-( ~)-3,4-dichloro-N-methyl-N-[2-(l-pyrrolidinyl)cycloexyllbenzen- 
acetamide methane sulfonate (U-50488H1, kindly provided by Upjohn 
Co. (Kalamazoo, MI). 
The binding of [3H]DIP to intact cells was evaluated using the method 
described by Cone et al. (26) with minor modifications. Briefly, GTl-1 
cells growing in multiwell plates were preincubated for 10 min in 0.5 ml 
binding buffer [50 mM Tris-HCl (pH 7.4), 1% BSA, and 0.5 mg/ml 
bacitracin] containing 100 mM NaCl at room temperature. During the 
last 2 min of the preincubation, the plates were kept at 4 C to adapt the 
cells to the assay incubation temperature. The preincubation buffer was 
then replaced with 0.5 ml binding buffer containing the tracer [3HlDIP. 
Nonspecific binding was assessed by the addition of 1 /.LM unlabeled 
naltrexone. For competition experiments, unlabeled opioids were added 
simultaneously to the tracer. After incubation at 4 C for 2 h, the cell 
monolayers were washed three times with DPBS, solubilized in 0.5 ml 
0.2 M NaOH, neutralized with 1 M HCl, mixed with 7 ml scintillation 
cocktail (Instagel, Packard, Milan, Italy), and counted in a Packard 1600 
CA liquid scintillation spectrometer with 60% efficiency. 
CAMP assay 
The intracellular CAMP accumulation was measured over a 15-min 
incubation period with 1 PM prostaglandin E, @‘GE,) or 10 /.LM pros- 
taglandin E, (PGE,; Sigma) as activators of adenylyl cyclase after a 
IO-min preincubation with 0.5 mM 3-isobutyl-1-methylxanthine (Sigma). 
A commercially available binding protein assay kit (Amershaml was 
used to evaluate CAMP levels in ethanol-extracted cells according to the 
manufacturer’s instructions. 
Statistical analysis 
Receptor binding experiments were optimized with the program 
Design (271, and the results were further analyzed by the program 
Ligand (28), adapted to a Macintosh computer by Dr. G. E. Rovati 
(Institute of Pharmacological Sciences, Milan, Italy). 
The dose-response curves were analyzed by means of a Macintosh 
version of the program Allfit (29), kindly provided by Dr. V. Guarda- 
basso (Cyanamid, Catania, Italy). 
Results 
Studies on GTl-1 cell membrane preparations 
Receptor binding experiments have shown the presence of 
specific binding of the opioid ligand 13H]DIP to crude mem- 
brane preparations obtained from GTI-1 cell homogenates. 
Such binding attains equilibrium in 30 min at 25 C and is 
totally inhibited by an excess (1 PM) of unlabeled nonselec- 
tive opioid ligands such as bremazocine and naltrexone, 
which leave a low (5%) residual nonspecific binding (data not 
shown). 
As illustrated in Fig. 1, the binding of [3H]DIP to mem- 
brane preparations of GTl-1 cells is saturable and charac- 
terized by a high affinity (Kd, 0.2 nM), which is of the same 
order of magnitude as that in membranes obtained from the 
whole mouse brain (&, 0.1 nM). The maximal binding ca- 
pacity (B,,,) of t3H]DIP, normalized per mg protein incu- 
bated, seems to be lower in GTl-1 cell membranes than in 
mouse brain (125 fmol/mg protein for GTl-1 cell mem- 
branes VS. 156 fmol/mg protein for mouse brain). However, 
the two results are not directly comparable due to the dif- 
0 mouse brain 0 GTl-1 cells 
Kd 0.1 ntvl Kd 0.2 nM 
Bmax 156 fmoUmg protein Bmax 125 fmoVmg protein 
1 I 
r I I I 1 
lo-9 2.10-g 3.1 o-9 
PH] DIPRENORPHINE (M/L) 
FIG. 1. Specific binding of increasing concentrations of t3HlDIP to 
mouse brain and GTl-1 cell membrane preparations. Nonspecific 
binding was determined in the presence of 1 FM naltrexone. The 
saturation isotherms were analyzed by the Ligand program (281, and 
the binding parameters B,, and I& were determined. The data are 
also represented as a Scatchard plot (inset) and are representative of 
two independent experiments performed in duplicate. 
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ferent sources of the starting materials (i.e. a homogeneous 
cell line VS. an extract of heterogeneous brain tissues con- 
taining different types of cells). 
As [3H]DIP is known to label with approximately equal 
affinity brain p, 8, and K sites, the possible presence in GTI-1 
cells of the different subclasses of opioid receptors and their 
relative proportions were further investigated by selective 
inhibition of the specific binding of [3H]DIP. The selective 
opioid ligands DAGO, DPDPE, and U50488H were used to 
inhibit the binding of f3HlDIP, respectively, to p-, 6, and 
K-receptors. Two concentrations of each selective ligand were 
used to obtain a submaximal and a maximal mask of their 
relative binding sites. The results show that at 1-nM concen- 
trations, the three specific ligands had no significant inhib- 
itory effect on [3HlDIP binding (Fig. 2). At higher concen- 
trations (100 no), only the specific Migand DPDPE inhibited 
(up to 60%) the specific binding of 13HlDIP to GTl-1 mem- 
branes (Fig. 2). The pure p- and k-ligands DAGO and 
U50488H were practically ineffective in inhibiting 13HlDIP 
binding even at the higher concentration (Fig. 2). These re- 
sults may be indicative of the presence of only &opioid- 
binding sites on the membranes of GTl-1 cells. 
The characteristics of the inhibitory effect of DPDPE on 
[3HlDIP binding were further investigated by heterologous 
displacement curves. The analysis of these curves shows that 
DPDPE inhibits the specific binding of 1 nM i3HlDIP on 
GTl-1 cell membranes in a dose-related fashion, with a Ki of 
5.5 no and maximal inhibition (>90%) at the l-PM concen- 
tration (Fig. 3). 
One of the characteristics of opioid receptors resides in the 
decrease in the binding of opioid agonists (but not of opioid 
antagonists) induced by the presence in the medium of 
monovalent ions, in particular sodium ions (30, 31). The 
potency of the agonist DPDPE in displacing [3H]DIP binding 
on GTl-1 membrane preparations was then assessed in the 
presence of sodium ions. As expected, the binding of the 
DAGO DPDPE U50488H 
FIG. 2. Selective inhibition of the specific binding of F3HlDIP (0.5 no) 
by p (DAGC)-, 6 (DPDPE)-, and K KJ50488H)-selective ligands. 
13HlDIP was incubated with 1 no (0) or 100 IM (M) of the specific 
opioid agonists. Values are the mean -C SEM of triplicate determina- 
tions obtained from two independent experiments. *, P < 0.05 us. 
[3H]DIP-specific binding in the absence of opioid agonists. 
OS025 * 
log dose DPDPE (M) 
FIG. 3. Inhibition of the binding of 13H1DIP to GTl-1 cell membrane 
preparations by the selective &agonist DPDPE. r3HlDIP (0.5 11~1 was 
incubated with various concentrations of DPDPE. The values repre- 
sent one of two independent experiments performed in triplicate. The 
& of DPDPE was calculated using the Ligand program (28). 
antagonist r3HlDIP was not changed in the presence of 100 
mM NaCl (data not shown), whereas a significant increase in 
the IC,, of DPDPE was observed (Table 1). 
Studies on intact GTl-1 cells 
To rule out the possibility that the results obtained might 
be due to artefacts linked to the mechanical disruption of 
membrane integrity and cytoskeletal ultrastructures during 
homogenization, the binding of [3HlDIP was also assessed in 
intact GTl-1 cells. The analysis of the saturation curve of 
[3HlDIP to intact GTl-1 cells shows that in these conditions, 
specific binding of the labeled ligand occurs; this is charac- 
terized by the same K, value (0.23 nM) previously observed 
in membrane preparations. The density of receptors labeled 
by t3H1DIP in intact cells appears to be 38 fmol/mg protein, 
corresponding to approximately 20,000 sites/cell, with a 
nonspecific binding of 5% (Fig. 4). The binding of [3HlDIP to 
intact GTl-1 cells is presumably due to an interaction with 
receptors located on the cellular membrane (26) and not to 
internalization of the tracer. In fact, an acid wash (PBS, pH 
3, for 6 mm at 4 Cl performed on intact GTl-1 cells previously 
incubated under standard conditions with 13HlDIP (see Ma- 
tcriuZs and Methods) removes more than 85% of the f3H1DIP 
bound to these cells. Selective inhibition of the specific bind- 
ing of [3H]DIP to intact GTl-1 cells also shows that only those 
ligands that bind preferentially the Z-opioid receptors (i.e. 
DPDPE) are able to inhibit the binding of the tracer (Table 2). 
DPDPE inhibits the binding of 13H1DIP to intact cells with a 
K of 14.5 nM, and its inhibitory potency is significantly 
TABLE 1. Effect of sodium ions on the potency of DPDPE to 
displace the binding of [3HJDIP to GTl-1 cell membrane 
preparations 
Treatment Go bd) 
Control 
NaCl(100 mu) 
15.1 + 1.6 
63.7 + 7.7” 
Values + SD were obtained by Alliit (29) analysis of competition 
curves, performed in triplicate. 
“P C 0.05 us. control. 
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Kd 0.23 nM 
Bmax 38 fmoi/mg protein 
,  -  I  -  I .  I  -  I .  I  
2. 10-g 4. 10-g 6. 1O-g 8. 1O-g 
[3H] DIPRENORPHINE (M/L) 
FIG. 4. Specific binding of increasing concentrations of 13HlDIP to 
intact GTl-1 cells. Nonspecific binding was determined in the pres- 
ence of 1 FM naltrexone. The saturation isotherms were analyzed by 
the Ligand program (281, and the binding parameters B,, and I& 
were determined. Data are representative of two independent exper- 
iments performed in duplicate. 
TABLE 2. Effects of several opioid agonists on the binding of 
13H1DIP to intact GTl-1 cells 
Agonists 
(100 m) 
‘8 of [%lDIF’ 
specific binding 
DAGO 
DPDPE 
U50488H 
102.0 i_ 3.9 
81.9 + 0.6” 
103.7 + 2.4 
Data are expressed as the mean t SE&f of two experiments 
performed in triplicates. 
a P < 0.05 us. percent specific binding of [3H]DIP in the absence of 
the agonists (100%). 
reduced, as in the studies on membrane preparations, by 
the presence of 100 mM NaCl in the incubation medium 
(Table 3). 
Opioid inhibition of CAMP accumulation in Gin-1 cells 
The effect of DPDPE on the activation of adenyl cyclase 
induced by different stimuli was studied in GTl-1 cells by 
measuring the intracellular accumulation of CAMP. As illus- 
trated in Fig. 5, the basal levels of CAMP found in control cells 
were not modified by a lo-PM concentration of the ii-opioid 
agonist DPDPE. The addition to GTI-1 cells of 1 PM PGE, 
dramatically enhanced CAMP accumulation (8.6fold over 
prestimulated levels at the end of the 15 mm of treatment). 
PGE, also showed a strong stimulatory effect on CAMP ac- 
cumulation. However, the stimulatory effects on the intra- 
cellular CAMP concentration induced by both PGE, and 
TABLE 3. Effect of sodium ions on the potency of DPDPE to 
displace the binding of [3H]DIP to intact GTl-1 cells 
Treatment IC,, (nM) 
Control 92.1 2 12.0 
NaCl(100 mu) 1138.2 i 106.9" 
Values t SD were obtained by Allfit (291 analysis of competition 
curves, performed in triplicate. 
a P < 0.05 vs. control. 
25 
FIG. 5. Inhibition of PGE,- and PGE,-stimulated CAMP accumula- 
tion in GTl-1 cells by the opioid delta agonist DPDPE. Cells were 
incubated for 30 min with 3-isobutyl-1-methylxanthine (0.5 mu) in 
serum-free medium; PGE, (1 FM) or PGE, (10 FM), alone or with 
DPDPE (10 ,LLM), was then added for the last 15 min of culture. Values 
are the mean F SEM of quadruplicate determinations obtained from 
two independent experiments. *, P < 0.05 vs. control; **, P < 0.05 vs. 
PG-treated cells. 
PGE, were significantly reduced by coincubation with 10 PM 
DPDPE by 44% and 33% respectively (Fig. 5). 
Discussion 
The results described in the present study provide the first 
evidence showing that LHRH-producing GTl-1 cells express 
opioid receptors. The nonselective opioid antagonist [3HlDIP 
binds with high affinity (0.2 nM) to both crude cell membrane 
preparations as well as intact GTl-1 cells. The binding af- 
finity of [3H]DIP to GTl-1 cells is similar to that reported for 
this opiate when tested on membrane preparations obtained 
from either rat brain or neuroblastoma cells (26, 32-35). 
The binding of 13H]DIP to GTl-1 cells is characterized by 
low nonspecific binding and is similar to that observed in 
crude membrane preparations of whole mouse brain. 
fH]DIP binds with approximately equal affinity to F-, 6, 
and fc-opioid receptors (22, 32, 36); consequently, it is not 
possible to discriminate, using only this approach, the type(s) 
of opioid receptor(s) present on GTl-1 cells. Selective dis- 
placement experiments performed with specific opioid li- 
gands revealed the presence only of binding sites of the 6 
type. Indeed, in the membrane preparation studies, the se- 
lective ligand for S-opioid receptors, DPDPE, strongly in- 
hibits (>90% at 1 PM) the binding of 13HlDIP, which, on the 
contrary, is not affected by selective ligands for the k- and 
K-opioid-binding sites. The K, for DPDPE (5.5 nM) calculated 
on the present results is very similar to the K, or & found for 
labeled DPDPE on 6 sites present in membrane preparations 
obtained from rodent brain or neuroblastoma cells (35,37- 
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39). The presence of only binding sites of the 6 type was also 
confirmed in intact GTI-1 cells (see below). 
A further characterization of these receptors was per- 
formed by analyzing their sensitivity to sodium ions. It is 
well known that the binding of CL- and &agonists is decreased 
in the presence of sodium ions, a phenomenon that does not 
occur when opioid antagonists are used. From the data ob- 
tained, it is evident that the presence of sodium in the in- 
cubation buffer induces a significant decrease in the potency 
of DPDPE to inhibit the binding of [3H]DIP to either mem- 
brane preparations or intact GTI-1 cells. This results in in- 
creases in the Ki and IC,,. 
As previously mentioned, the presence of 6-opioid- 
binding sites was confirmed when the binding experi- 
ments were repeated on intact GTl-1 cells. However, the 
selective inhibitory effect of the 6-ligand DPDPE on the 
binding of [3H]DIP was slightly lower in intact GTl-1 cells 
than that found in crude membrane preparations. It is 
well known that the binding of p- and a-agonists is de- 
creased not only in the presence of sodium ions, but also 
by GTP (34). As the binding experiments on intact GTl-1 
cells were performed in a sodium-free buffer, it is possible 
that the decreased displacing activity of DPDPE might be 
due to the presence of GTP or to a combined effect of GTP 
and residual intracellular sodium (31). Recently, the clon- 
ing of b-opioid receptors has been reported (40-42); an 
assessment of the expression of messenger RNA for the 
&opioid receptors in GTI-1 cells is presently under way 
and will provide a definitive evidence of their presence in 
these LHRH-secreting cells. 
It is well known that opioids may exert inhibitory effects 
on the stimulated accumulation of CAMP in several cells and 
tissues (23, 43, 44). To investigate whether the 6-opioid re- 
ceptors identified on GTl-1 cells are functional, the ability of 
the &agonist DPDPE to inhibit the stimulation of CAMP 
accumulation induced in GTl-1 cells by treatment with two 
known activators of adenylyl cyclase, PGE, and PGE,, was 
analyzed (45). The results obtained clearly showed that both 
PGs are strong stimulators of CAMP accumulation in GTl-1 
cells, and that the activation of Gopioid receptors by DPDPE 
leads to a significant decrease in the stimulated CAMP levels. 
The data presented here are consistent with the numerous 
observations of an inhibitory role exerted by the opioids on 
intracellular CAMP accumulation (43-47) and indicate that 
the &receptors reported on GTI-1 cells are functional. In 
addition, the ability to inhibit CAMP accumulation as well as 
the sensitivity to sodium ions suggest a functional coupling 
of the &receptor subtype present in GTl-1 cells to intracel- 
lular effector molecules such as the GTP-binding proteins 
(22, 23). In experiments presently in progress, it has been 
shown that the S-opioid agonist DPDPE inhibits LHRH se- 
cretion in GTl-1 cells elicited by forskolin (Maggi, R., F. 
Pimpinelli, L. Martini, and F. Piva, in preparation). 
The presence of opioid-binding sites on the subclone of 
GTl cells used in the present experiments is relevant, espe- 
cially in light of the possible role of these receptors in the 
control of LHRH release and expression. If one assumes that 
GTl cells represent a good model for the study of LHRH- 
secreting neurons, the obvious conclusion from these data is 
that endogenous opioid peptides may influence LHRH se- 
cretion by acting directly on LHRH-secreting neurons. A 
second conclusion would be that this effect of the opioids is 
mediated by the &subclass of receptors. Obviously, it must 
be pointed out that the present data do not exclude the 
possibility that opioids act on the release of LHRH via other 
mechanisms (see below). As mentioned in the introduction, 
a large body of evidence implicates opioid peptides in the 
central mechanisms controlling gonadotropins and LHRH 
secretion (1,15,17-20). The prevailing theory proposes that 
opioid neurons have synaptic contacts with intermediate 
neurons, which, in turn, influence LHRH neurons via the 
local release of their respective neurotransmitters (18, 48). 
However, a few reports have demonstrated that, at least in 
rats (4951), monkeys (52), and cows (53), opioid neurons 
(particularly POMC or /.3-endorphin reactive) may entertain 
direct synaptic contacts with hypothalamic LHRH-immuno- 
reactive neurons, suggesting the possibility of a direct effect 
of physiological opioids. In contradistinction with the 
present data, which shows the presence of &receptors on 
LHRH-producing neurons, a number of data obtained in 
viva, especially in the rat, support the view that opioids affect 
LHRH release mainly through the interaction with opioid 
receptors of the p type (54-57). However, a few studies have 
also implicated 6 (58-60)- and K (58,59)-receptors in such a 
mechanism. For instance, Leadem et aZ. (58,59) have shown 
that A-agonists, including DPDPE, induce a biphasic effect 
on LH secretion in ovariectomized rats after intraventricular 
injection. In this connection, one may also point out that 
/.3-endorphin binds with similar affinities to p and 6 sites (22, 
36). It must be recalled that the relative proportions of opioid 
receptor subtypes are different in the brains of various an- 
imal species (61). For instance, in the forebrain of the mouse 
(the species from which GTl cells are derived), there is 25% 
more &receptor and 40% less p-receptor than in the forebrain 
of the rat, suggesting a predominantly &receptor composi- 
tion in the mouse brain (61). Moreover, in the mouse, both 
the hypothalamus and preoptic area contain the same 
amounts of p- and Gopioid receptors (62), whereas in the rat, 
the concentration of A sites is extremely low in the hypo- 
thalamus (39, 61, 63), a structure in which a relatively high 
concentration of p-receptors is present in this species (61,63). 
In conclusion, from the data here presented, when ana- 
lyzed in conjunction with the evidence just described, we 
hypothesize that the effects of physiological opioid peptides 
on LHRH secretion consist of two distinct components: the 
first, acting directly on the &receptors present on the LHRH- 
synthesizing neurons, and the second acting via intermediate 
neurons, where opioids probably interact mainly with the 
F-receptor subfamily. 
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